[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)]

Zhongguo Fei Ai Za Zhi. 2020 Mar 20;23(3):136-141. doi: 10.3779/j.issn.1009-3419.2020.03.02. Epub 2020 Feb 20.
[Article in Chinese]

Abstract

Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.

【中文题目:新型冠状病毒肺炎疫情期间肺癌患者临床管理】 【中文摘要:自2019年12月底以来,湖北省武汉市陆续发现多例新型冠状病毒肺炎(简称:新冠肺炎,2019 novel coronavirus disease,COVID-19),并在全国范围内蔓延。随着新冠肺炎疫情的蔓延,肺癌患者的常规医疗受到影响。由于肺癌患者接受抗肿瘤治疗后免疫力低,合并感染后症状重,应是疫情防治的重点对象,肺癌患者对新冠肺炎的防范措施日益受到关注。复杂严峻的新冠肺炎疫情下,接受抗肿瘤治疗的肺癌患者如出现发热及呼吸道症状,更需要仔细地进行鉴别诊断,评估新冠肺炎感染的风险。对于肺癌患者,在新冠肺炎疫情期间,需要进行精细化和个体化的管理,最大程度地保护患者,有效防范新冠肺炎。】 【中文关键词:肺肿瘤;患者管理; 新型冠状病毒肺炎】.

Keywords: 2019 novel coronavirus disease; Lung neoplasms; Patient management.

MeSH terms

  • Betacoronavirus* / pathogenicity
  • COVID-19
  • China
  • Coronavirus Infections* / epidemiology
  • Disease Outbreaks*
  • Disease Susceptibility
  • Humans
  • Immunocompromised Host*
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / therapy
  • Patient Care Planning
  • Pneumonia, Viral* / epidemiology
  • Risk
  • SARS-CoV-2

Grants and funding

本文受国家“十三五”重大新药创制专项子课题“创新药物临床评价示范性平台建设”(No.2019ZX09734001-002)和北京市自然科学基金(No.7194311)资助